Aureus Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $224K | Sell |
3,689
-15,997
| -81% | -$933K | 0.01% | 210 |
|
|
2025
Q4 | $1.06M | Hold |
19,686
| – | – | 0.07% | 93 |
|
|
2025
Q3 | $888K | Sell |
19,686
-34,384
| -64% | -$1.61M | 0.06% | 96 |
|
|
2025
Q2 | $2.5M | Buy |
54,070
+17,036
| +46% | +$836K | 0.16% | 66 |
|
|
2025
Q1 | $2.26M | Buy |
37,034
+31,975
| +632% | +$1.86M | 0.16% | 68 |
|
|
2024
Q4 | $286K | Buy |
5,059
+166
| +3% | +$9.28K | 0.02% | 166 |
|
|
2024
Q3 | $253K | Buy |
+4,893
| New | +$230K | 0.02% | 178 |
|
|
2024
Q2 | – | Sell |
-6,922
| Closed | -$375K | – | 203 |
|
|
2024
Q1 | $375K | Sell |
6,922
-1,244
| -15% | -$63.4K | 0.03% | 139 |
|
|
2023
Q4 | $419K | Hold |
8,166
| – | – | 0.03% | 130 |
|
|
2023
Q3 | $474K | Sell |
8,166
-33,087
| -80% | -$2.03M | 0.04% | 121 |
|
|
2023
Q2 | $2.64M | Sell |
41,253
-1,117
| -3% | -$74.9K | 0.2% | 66 |
|
|
2023
Q1 | $2.94M | Buy |
42,370
+62
| +0.1% | +$4.37K | 0.23% | 62 |
|
|
2022
Q4 | $3.04M | Buy |
42,308
+5,371
| +15% | +$405K | 0.26% | 56 |
|
|
2022
Q3 | $2.63M | Hold |
36,937
| – | – | 0.23% | 59 |
|
|
2022
Q2 | $2.84M | Buy |
36,937
+22,266
| +152% | +$1.7M | 0.23% | 62 |
|
|
2022
Q1 | $1.07M | Buy |
14,671
+105
| +0.7% | +$7.05K | 0.07% | 101 |
|
|
2021
Q4 | $908K | Sell |
14,566
-21,940
| -60% | -$1.29M | 0.06% | 101 |
|
|
2021
Q3 | $2.16M | Hold |
36,506
| – | – | 0.14% | 74 |
|
|
2021
Q2 | $2.44M | Buy |
+36,506
| New | +$2.38M | 0.16% | 71 |
|
|
2020
Q4 | – | Sell |
-5,160
| Closed | -$311K | – | 187 |
|
|
2020
Q3 | $311K | Sell |
5,160
-310
| -6% | -$18.7K | 0.03% | 141 |
|
|
2020
Q2 | $322K | Sell |
5,470
-600
| -10% | -$35.9K | 0.04% | 127 |
|
|
2020
Q1 | $338K | Sell |
6,070
-200
| -3% | -$12.2K | 0.05% | 112 |
|
|
2019
Q4 | $402K | Buy |
6,270
+200
| +3% | +$11.5K | 0.04% | 125 |
|
|
2019
Q3 | $308K | Hold |
6,070
| – | – | 0.04% | 136 |
|
|
2019
Q2 | $275K | Sell |
6,070
-2,453
| -29% | -$114K | 0.03% | 147 |
|
|
2019
Q1 | $407K | Sell |
8,523
-140,728
| -94% | -$7.01M | 0.05% | 114 |
|
|
2018
Q4 | $7.76M | Sell |
149,251
-69,480
| -32% | -$3.73M | 1.22% | 31 |
|
|
2018
Q3 | $13.6M | Buy |
218,731
+14,925
| +7% | +$886K | 1.73% | 28 |
|
|
2018
Q2 | $11.3M | Buy |
203,806
+4,985
| +3% | +$269K | 1.55% | 28 |
|
|
2018
Q1 | $12.6M | Sell |
198,821
-2,569
| -1% | -$165K | 1.89% | 26 |
|
|
2017
Q4 | $12.3M | Sell |
201,390
-591
| -0.3% | -$37K | 1.91% | 23 |
|
|
2017
Q3 | $12.9M | Buy |
201,981
+1,751
| +0.9% | +$102K | 2.04% | 23 |
|
|
2017
Q2 | $11.2M | Buy |
200,230
+12,324
| +7% | +$671K | 1.88% | 27 |
|
|
2017
Q1 | $10.4M | Buy |
187,906
+23,663
| +14% | +$1.3M | 1.8% | 29 |
|
|
2016
Q4 | $9.6M | Buy |
164,243
+160,530
| +4,323% | +$8.78M | 1.88% | 27 |
|
|
2016
Q3 | $200K | Buy |
+3,713
| New | +$239K | 0.04% | 144 |
|
|
2016
Q2 | – | Sell |
-3,340
| Closed | -$213K | – | 132 |
|
|
2016
Q1 | $213K | Sell |
3,340
-328
| -9% | -$20.7K | 0.05% | 96 |
|
|
2015
Q4 | $252K | Buy |
3,668
+171
| +5% | +$11.3K | 0.06% | 114 |
|
|
2015
Q3 | $207K | Sell |
3,497
-62
| -2% | -$3.93K | 0.05% | 145 |
|
|
2015
Q2 | $237K | Buy |
3,559
+1
| +0% | +$66 | 0.05% | 149 |
|
|
2015
Q1 | $230K | Buy |
+3,558
| New | +$223K | 0.05% | 135 |
|
Other funds holding BMY
VCM
VPM
Aureus Asset Management's BMY Position: Q1 2026 in Review
Aureus Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 81% in Q1 2026, selling an estimated $933K and leaving 3,689 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #210.
Aureus Asset Management first reported a position in BMY in Q1 2015 and has held it in 41 quarters since. The position peaked at $13.6M in Q3 2018. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Aureus Asset Management held 3,689 shares of Bristol-Myers Squibb worth $224K as of Q1 2026.
- Aureus Asset Management sold 15,997 Bristol-Myers Squibb shares in Q1 2026, an estimated $933K.
- Bristol-Myers Squibb made up 0.01% of Aureus Asset Management's portfolio in Q1 2026, its #210 holding.
- Aureus Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 41 quarters since.
- Aureus Asset Management's Bristol-Myers Squibb position peaked at $13.6M in Q3 2018.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Aureus Asset Management's 13F filing for Q1 2026, filed 13 May 2026.